Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 17(14): 5015-26, 2009 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-19525116
2.
J Med Chem ; 52(10): 3385-96, 2009 May 28.
Artigo em Inglês | MEDLINE | ID: mdl-19459652

RESUMO

A series of novel imidazoline derivatives was synthesized and evaluated as neuropeptide Y (NPY) Y5 receptor antagonists. Optimization of previously reported imidazoline leads, 1a and 1b, was attempted by introduction of substituents at the 5-position on the imidazoline ring and modification of the bis(4-fluorphenyl) moiety. A number of potent derivatives without human ether-a-go-go related gene potassium channel (hERG) activity were identified. Selected compounds, including 2a, were shown to have excellent brain and CSF permeability. Compound 2a displayed a suitable pharmacokinetic profile for chronic in vivo studies and potently inhibited D-Trp(34)NPY-induced acute food intake in rats. Oral administration of 2a resulted in a potent reduction of body weight in a diet-induced obese mouse model.


Assuntos
Fármacos Antiobesidade/química , Canais de Potássio Éter-A-Go-Go/metabolismo , Imidazolinas/farmacologia , Obesidade/tratamento farmacológico , Receptores de Neuropeptídeo Y/antagonistas & inibidores , Animais , Fármacos Antiobesidade/síntese química , Fármacos Antiobesidade/farmacologia , Encéfalo/metabolismo , Líquido Cefalorraquidiano/metabolismo , Modelos Animais de Doenças , Descoberta de Drogas , Canal de Potássio ERG1 , Humanos , Imidazolinas/síntese química , Imidazolinas/química , Farmacocinética , Ligação Proteica/efeitos dos fármacos , Ratos , Relação Estrutura-Atividade , Redução de Peso/efeitos dos fármacos
3.
Bioorg Med Chem Lett ; 19(6): 1670-4, 2009 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-19233647

RESUMO

Novel imidazoline derivatives were discovered to be potent neuropeptide Y Y5 receptor antagonists. High-throughput screening of Merck sample collections against the human Y5 receptor resulted in the identification of 2,4,4-triphenylimidazoline (1), which had an IC(50) of 54nM. Subsequent optimization led to the identification of several potent derivatives.


Assuntos
Química Farmacêutica/métodos , Imidazóis/química , Receptores de Neuropeptídeo Y/química , Animais , Encéfalo/metabolismo , Ácidos Carboxílicos/química , Líquido Cefalorraquidiano/metabolismo , Desenho de Fármacos , Humanos , Concentração Inibidora 50 , Camundongos , Modelos Químicos , Estrutura Molecular , Relação Estrutura-Atividade
4.
J Org Chem ; 62(21): 7192-7200, 1997 Oct 17.
Artigo em Inglês | MEDLINE | ID: mdl-11671827

RESUMO

Reaction of 3-butenyl radicals generated by photolysis of variously substituted Barton esters (both open-chain 1a-d and cyclohexyl 1e-h) with CF(2)=CCl(2) gave a mixture of cyclized products (cyclopentanes 6 and 8 and cyclohexanes 7 and 9) as well as noncyclized products (4and 5) in various ratios depending on the substitution pattern at the olefinic moiety. The product ratios of [cyclization (6 + 7 + 8 + 9):noncyclization (5)] for 1 with more alkyl substituents on the CC double bond were greater than those for 1 with fewer substituents. The products ratio of [5-exo (6 + 8):6-endo (7 + 9)] was influenced by a steric effect. Photoreaction of Barton ester 2 with CF(2)=CCl(2) gave a mixture of cyclohexanes 16 and 17 as well as noncyclized 14 and 15. Dehydrochlorination of decalins 7g and 7h followed by oxidation of sulfide and [2,3]sigmatropic rearrangement of the allyl sulfoxide gave octahydronaphthalenones 23 and 27, respectively.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA